Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Izzy who wrote (4576)	6/28/1998 3:55:00 PM
From: Izzy	Read Replies (2) \| Respond to of 6136

Today's San Diego Tribune: "Immune Response, Agouron Pharmaceuticals pact has potential." I'm unable to cut/paste the article or retype the whole thing. "However, James McCamant, editor of the Medical Technology Stock Letter in Berkeley, says Agouron stock is "woefully undervalued," in part because of a Merrill Lynch prediction that the annual growth of the HIV market will slow. That estimate is in error, McCamant says. Agouron, which has been trading in the lows $30s, is a buy under $40, he says." That's what I say, too.